

Alchemia Announces Sale of Fondaparinux Intellectual Property

Brisbane, Australia; 25 September 2015: Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced that it has entered into a binding term sheet for the sale of the worldwide exclusive intellectual property rights to fondaparinux sodium, its generic anti-coagulant drug, to Dr. Reddy's Laboratories ("Dr. Reddy's", NYSE: RDY).

Under the binding terms of the sale, Alchemia will receive US\$17.5 million (approximately AU\$24.3 million) in cash from Dr. Reddy's upon the closing of the transaction. In addition to the agreed sale consideration, the Company received a payment of US\$1.15 million for its share of net profit from US-only sales of fondaparinux for the quarter ending 30 June 2015. Should the transaction be approved by shareholders and the transaction subsequently closed, the Company will not be entitled to receive any further profit share revenues from fondaparinux sales.

The sale is conditional on shareholder approval, as the sale constitutes a disposal of the Company's main undertaking per the ASX Listing Rules. Shareholder approval is expected to be sought at the Company's upcoming annual general meeting to be held in November this year. The Company is in the process of seeking an independent expert's report to assist shareholders in their decision on how to vote on the transaction.

In 2007, Alchemia granted Dr. Reddy's non-exclusive rights to the manufacture of fondaparinux sodium in API (Active Pharmaceutical Ingredient) form, and exclusive rights to market fondaparinux in the North America. In exchange for these manufacturing and marketing rights, Alchemia was entitled to receive 50% of the net profit generated from sales of fondaparinux in North America. Dr. Reddy's is responsible for finishing of the product, all regulatory filings, and market launch.

The Company's generic fondaparinux was approved by the US Food and Drug Administration ("FDA") in July 2011, and launched by Dr. Reddy's in the US shortly after. To date, the Company has received a total of US\$21.4 million (AU\$23.3 million) in revenues from its share of net profits for US sales of fondaparinux. These revenues are net of (after) the Company's contribution of US\$5.0 million (AU\$5.5 million) towards cost of goods improvements.

In 2012, the Company granted Dr. Reddy's exclusive rights to market fondaparinux in all territories, other than North America, in exchange for an agreed share of the net profits generated from sales in those territories. In addition to the US, fondaparinux is currently being sold in Canada and India, however sales of fondaparinux in these territories are yet to generate any profits. Fondaparinux is yet to be launched in any other territory.

About Fondaparinux

Fondaparinux is a generic version of the anticoagulant drug Arixtra®. Arixtra® is approved in the US and Europe for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and is also indicated for the prevention of DVT after major surgery, such as knee and hip replacement.

Fondaparinux is recommended by the American College of Chest Physicians and received the European Society of Cardiology's highest recommendation for use in acute coronary syndrome. Fondaparinux is a synthetic pentasaccharide which is difficult to manufacture on a commercial scale. Alchemia has granted patents over novel synthetic pathways that prevent others from using Alchemia's proprietary process to manufacture fondaparinux until at least 2022.

About Alchemia

Alchemia is a drug discovery and development company marketing fondaparinux in the US and other markets, via partner Dr. Reddy's Laboratories. For more information, log on to: www.alchemia.com.au

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because it believes Good Health Can't Wait. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – the company offers a portfolio of products and services that include active pharmaceutical ingredients, ("APIs"), custom pharmaceutical services, generics, biosimilars and differentiated formulations. With operations in 26 countries across the globe, the major therapeutic areas of Dr. Reddy's are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com

Contacts

Alchemia Limited

Jenni Pilcher

Chief Financial Officer

Tel: +61 7 3340 0200

For personal use only